Relmada Therapeutics Inc. (4E2)
XDUS
Closed
Aug 24, 2026
Day's Range
3.7852 wk Range
0.5100Overview - 4E2 - Relmada Therapeutics Inc.
Key Statistics
Valuation
P/E (Trailing)
‪-2.62‬
PEG Ratio
‪0.04‬
Price / Book
‪2.06‬
Profitability
Return on Assets
‪-61.04%‬
Return on Equity
‪-66.33%‬
Ownership
Shares Outstanding
106.66M
Price stats
50-Day Avg
‪4.91‬
200-Day Avg
‪4.63‬
Peers - 4E2 - Relmada Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XDUS.
- 4E2XDUSRelmada Therapeutics Inc.+86.32%52-week change-2.62P/E (Trailing)—Profit Margin
- 3920XDUSSpyre Therapeutics, Inc.+84.37%52-week change-46.21P/E (Trailing)—Profit Margin
- 42ZXDUSRevolution Medicines Inc.+82.81%52-week change-30.12P/E (Trailing)—Profit Margin
- 87EXDUSDianthus Therapeutics Inc.+78.20%52-week change-22.50P/E (Trailing)—Profit Margin
- 5NRAXDUSNanobiotix S.A. American Depositary Shares+77.55%52-week change—P/E (Trailing)—Profit Margin
- 5NRXDUSNanobiotix S.A.+77.54%52-week change—P/E (Trailing)—Profit Margin
- 7BGXDUSOncoinvent ASA+75.21%52-week change-0.06P/E (Trailing)—Profit Margin
Profile Summary - 4E2 - Relmada Therapeutics Inc.
About
Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapies for central nervous system disorders and oncology indications. Its primary efforts center on NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel designed for the treatment of…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
